Oral Gut-Restricted Targeted Therapy for IBD: A Pipeline Review

Area of Science:

• Gastroenterology
• Pharmacology
• Drug Delivery Systems

Background:

• Oral gut-restricted therapies are emerging for inflammatory bowel disease (IBD) to target the intestinal mucosa with minimal systemic exposure.
• Advances in molecular engineering and formulation enable oral agents designed for local gastrointestinal action.

Purpose of the Study:

• To review the principles of oral gut-restricted drug delivery in IBD.
• To analyze factors contributing to the discontinuation of past clinical development programs for ulcerative colitis and Crohn's disease.
• To identify lessons for optimizing future IBD therapy development.

Main Methods:

• Narrative review of biological, pharmacokinetic, and formulation principles.
• Analysis of discontinued clinical development programs for oral gut-restricted therapies in IBD.
• Examination of the current clinical trial pipeline for evolving development strategies.

Main Results:

• Recurring factors for discontinuation include limited efficacy, inadequate intestinal exposure, formulation challenges, and high placebo rates.
• Manufacturing variability and strategic decisions also impacted development outcomes.
• Current pipeline shows increased focus on local drug levels, mucosal pharmacodynamics, and localized endpoints.

Conclusions:

• Successful translation of oral gut-restricted therapies requires aligning mechanism of action, drug delivery, pharmacodynamics, and clinical trial design.
• Lessons learned from past programs are crucial for improving the success rate of future IBD treatments.
• Emphasis on local tissue drug levels and pharmacodynamic readouts is key for interpreting early efficacy signals.